Can a Camera-Verified Remote Breath Test Prove Continuous Abstinence? A 2023 Treatment Study

Quick answer: No. A camera-assisted, remotely transmitted breath-alcohol test documents a particular instrument reading associated with a particular attempted test, not continuous proof that a person consumed no alcohol between tests. A 2023 randomized outpatient-treatment feasibility study found that adding scheduled wireless breath testing was associated with higher self-reported treatment-motivation scores at selected follow-up points. It did not validate the device as continuous surveillance, measure participants’ blood ethanol directly, or establish the reliability of a specific result in court. The distinction matters whenever remote test records are offered as evidence of abstinence, relapse, intoxication, or compliance.

What did the original scientific study actually examine?

Frank D. Buono and colleagues published “Feasibility of a remotely monitored blood alcohol concentration device to facilitate treatment motivation” in Drug and Alcohol Dependence Reports in 2023. The investigators enrolled adults receiving in-home outpatient treatment for alcohol use disorder in Connecticut. The stated research question was whether adding a remote breathalyzer could enhance treatment motivation and perceived ability to resist drinking, compared with otherwise available treatment services.

This was a parallel-group randomized study, reported as a secondary analysis of a feasibility investigation. Participants received either the existing in-home treatment program alone (treatment as usual, TAU), or that program plus a wireless Soberlink breath-testing device (experimental group, EP). The assigned treatment period lasted three months, with an assessment six weeks later. Investigators recruited from July 2020 through December 2022 and collected questionnaires and interviews as well as device-use information.

The study was an evaluation of a treatment-support strategy. It was not a head-to-head analytical validation against simultaneous venous or whole-blood gas chromatography, a prospective forensic chain-of-custody study, or a controlled experiment testing whether a negative scheduled breath reading excludes all drinking since the preceding sample.

How many people participated—and what denominators matter?

The investigators reported recruiting 117 people, of whom 96 qualified. Ultimately, 43 experimental-group participants and 32 treatment-as-usual participants completed the study, or 75 completers in total. The experimental and comparison groups therefore differed in size at completion. Attrition, including unequal loss between groups, limits how much confidence should be placed in estimated treatment differences.

These denominators must not be interchanged. For example, “43 experimental-group completers” is not the denominator for all 117 recruits, and a count of uploaded breath submissions is not the same as a count of persons proven continuously alcohol-free.

What did the remote breathalyzer measure?

The experimental intervention used a handheld fuel-cell alcohol sensor with wireless reporting. The device incorporated a camera and facial-recognition process intended to associate a sample with the enrolled participant. The authors described instrument accuracy as plus or minus 0.005 BAC units; that is a performance statement reported in the paper, not an independent analytical validation established by this randomized treatment study.

The investigators used the term “blood alcohol concentration” when discussing breathalyzer output. Scientifically, however, a fuel-cell instrument detects alcohol from an exhaled-breath sample. A screen expressed in blood-alcohol-style units is not a separately collected venous specimen, a headspace gas-chromatographic blood result, or direct evidence of ethanol within brain tissue. Conversions, sampling conditions and instrumentation affect what a number can reasonably mean. See the site’s breath-alcohol measurement guide for the distinction between measured breath and inferred blood concentrations.

The paper did not describe a controlled paired venous-blood reference method that would allow calculation of individual sensor bias, a blood-to-breath partition ratio, sensitivity and specificity for an independent BAC threshold, or a validated uncertainty interval for any participant’s true whole-blood alcohol concentration. Its treatment findings therefore cannot be presented as proof of a particular forensic analytical error rate.

Do two scheduled tests per day demonstrate uninterrupted abstinence?

No. Two tests per day are discrete sampling events. The protocol allowed a two-hour testing window and a further one-hour late window; tests performed outside the scheduled window were recorded as unscheduled. When a result was positive or identity could not be verified, the system scheduled another test approximately 30 minutes later. A positive test could generate an email containing its time and value for the study coordinator and clinical team.

A negative result at a documented time is evidence about that submitted sample under the device’s reporting conditions. It is not a continuous trace covering the intervening hours. Even a set of negative readings cannot exclude every episode of alcohol intake between samples; the possible detectability of any episode depends on when drinking occurred, its magnitude, subsequent metabolism, the device’s actual sampling and reporting thresholds, and whether the requested test was successfully completed.

Equally, a missing test is a missing observation, not an instrument measurement of a positive ethanol concentration. An identity failure is a verification problem; it is not itself analytical detection of ethanol. Any system that combines positive, missed and identity-unverified events for administrative purposes should preserve the underlying categories so a reviewer does not mistake an operational alert for a measured alcohol result.

What improvement in treatment motivation did investigators find?

The University of Rhode Island Change Assessment (URICA) questionnaire is a self-report measure related to stages of behavior change. The paper found a statistically significant interaction between assignment group and assessment time for the URICA composite: F(2.145, 145.89) = 3.719, p = 0.024. Bonferroni-adjusted comparisons favored the device group at the two-month evaluation and at the six-week follow-up, but the authors did not report a significant between-group difference at discharge.

At two months, the reported URICA composite means were 7.126 (SD 1.29) for the device group and 6.323 (SD 1.86) for treatment as usual. At the follow-up, they were 7.116 (SD 1.32) and 6.121 (SD 2.29), respectively; both specified between-group contrasts met the authors’ reported p < 0.05 criterion. These are questionnaire scale scores, not concentrations of alcohol or counts of proven drinking episodes.

The Alcohol Abstinence Self-Efficacy Scale (AASE) addresses temptation and perceived confidence in resisting drinking in different situations. Its temptation composite decreased over time across both groups: F(1, 68) = 15.397, p < 0.01. For confidence, the paper reported no statistically significant main effects or interaction comparing groups over time. At follow-up, the nominal means (13.78 versus 11.92) did not differ significantly (p = 0.142). Thus, the results do not support a blanket assertion that wireless breath testing improved every motivational or self-efficacy outcome.

How do the measurement and outcome categories differ?

These categories are not interchangeable. For a true directly analyzed blood-alcohol specimen, an entirely different collection, laboratory method, calibration and quality-control record is needed; see the site’s blood-alcohol headspace GC-FID evidence guide.

What operational limitations did the study reveal?

Participant interviews described the convenience and treatment-support role of having an at-home device. Some also described difficulties involving battery charge, connectivity or equipment. The authors reported that 22% of interviewed patients had battery or service problems; two reported defective devices and received replacements. Qualitative impressions can identify implementation problems and patient preferences, but do not independently establish the biochemical correctness of each recorded result.

The paper’s breathalyzer-use table reported 6,561 completed tests in the experimental group. That is a count of test submissions, not proof of 6,561 distinct alcohol-free intervals or laboratory-confirmed results. The table’s adherence categories and percentage formatting warrant careful review before calculating a compliance percentage; no new percentage should be reconstructed from ambiguous row labels.

The protocol included a retest following positive results or verification difficulties. Whether a particular real-world sequence is consistent with residual mouth alcohol, an unsuccessful first sample, a connection failure or an actual drinking event cannot be determined from these aggregate trial findings. An individual case requires its own complete raw instrument and administrative records.

Why does the study not validate court-ordered sobriety monitoring?

The researchers recruited voluntary adults receiving outpatient alcohol-use-disorder care; importantly, the published eligibility criteria excluded people with current or pending legal action. Consequently, the paper does not directly estimate performance in court-ordered supervision, disputed custody monitoring, probation testing, post-arrest evaluations or litigation-specific chain-of-custody settings.

The population difference matters because instructions, incentives, opportunities for missed testing, consequences of an unverified test and the clinical reason for monitoring can all differ from those in a voluntary treatment program. That does not prove a device will fail in a legal setting. It means this particular feasibility study does not establish how well the device will work there.

Nor did this trial test intoxicated driving, memory, reaction time, field sobriety tests or crash outcomes. A treatment-motivation difference is not a motor-performance measurement, an impairment threshold or an individual causal opinion. A person may report improved motivation without supplying objective evidence of continuous abstinence; conversely, a problematic test record alone does not diagnose impaired driving or explain a particular incident.

What records are necessary for a case-specific scientific review?

A defensible evaluation begins with the underlying evidence, rather than the device brand or an abbreviated compliance dashboard. Relevant items can include: each actual time stamp and time zone, scheduled testing windows, completed and missed-test codes, original numerical readings and units, instrument model and serial identifier, maintenance and calibration history, test-quality flags, identity-verification outcomes, recorded photographs where lawfully available, retest sequences, connectivity logs, software definitions, data exports, operator instructions and the rules used to generate alerts.

Investigators should distinguish an event actually measured by the sensor from an event inferred by administrative software. A positive ethanol detection, a camera mismatch and a missed test can carry different scientific explanations. A reported value also should remain connected to the measurement’s specimen, instrument, threshold and time. The site’s specimen-collection and evidentiary integrity guide explains related record-preservation principles.

Without the complete record, claims about tampering, user identity, missing-test causes, analytic precision or the timing and amount of alcohol ingestion remain open questions. These are not matters resolved by the published trial’s group-level motivation scores.

What does this study justify—and what remains uncertain?

Buono and colleagues provide preliminary support for remote breath testing as a feasible adjunct to treatment for selected adults with alcohol use disorder, with improved self-reported motivation at specified assessments. They also report operational problems and do not find significant improvement in all self-efficacy outcomes. Their design and attrition limit generalization beyond the studied outpatient setting.

What the study does not justify is the proposition that a camera-equipped, twice-daily breath testing program continuously proves abstinence; that software identity checks substitute for chemical validation; that a manufacturer-stated accuracy figure was independently established in the trial; or that a particular individual’s relapse, psychomotor impairment, compliance violation or incident causation has been scientifically demonstrated. Those questions require distinct instruments, measures and case-specific evidence.

Frequently asked questions

Does a zero breathalyzer reading prove that the person did not drink earlier that day?

No. It reflects a result at the sampling time, under the instrument’s limits and test conditions. The intervening interval is not continuously measured by a twice-daily test protocol.

Is a remote breathalyzer’s reported “BAC” a laboratory blood result?

No. The instrument described in the study samples exhaled breath. Displaying a blood-style unit does not mean venous whole blood was collected or tested by a validated forensic laboratory method.

Does facial recognition prove that every test was correctly attributed?

The software is intended to support identity verification. This trial did not quantify an independent, case-specific false-identification rate for every event; original verification records must be examined.

Should a missed test be called a positive alcohol reading?

Not scientifically. A missed test is an absent scheduled measurement. Its administrative treatment may be separately defined by a program, but it is not itself an ethanol assay.

Did the experimental group become definitively more abstinent than the comparison group?

The reported secondary findings concern motivation and self-efficacy questionnaires, alongside device feasibility. They do not establish a universal or continuous biochemical abstinence advantage for each participant.

Did the study independently verify Soberlink’s claimed analytical accuracy?

No. The authors report a device accuracy specification, but the randomized comparison did not include a systematic paired reference-whole-blood validation sufficient to establish a forensic individual measurement error distribution.

Can this 2023 trial alone prove an individual legal compliance violation or impairment?

No. The trial excluded people with pending legal action and did not test legal compliance, workplace function or driving impairment. Those questions require the actual event records and independent context.

Primary research and scope

Buono FD, Polonsky M, Sprong ME, Aviles A, Cutter CJ. Feasibility of a remotely monitored blood alcohol concentration device to facilitate treatment motivation. Drug and Alcohol Dependence Reports. 2023;9:100202. doi:10.1016/j.dadr.2023.100202.

This analysis is an interpretation of the study’s published methods, results and limitations for scientific education. A monitored person’s actual sample history, laboratory records and governing procedures are indispensable before expressing an opinion about that person.